1. mRNA-1083, a multicomponent mRNA vaccine, demonstrated noninferior immunogenicity in adults aged 50 and older, with superior immune responses against multiple vaccine-matched strains in some subgroups.
2. The trial involved 8,015 participants and found that mRNA-1083 induced higher immune responses against influenza and SARS-CoV-2, with an acceptable safety profile.
3. Primary noninferiority endpoints were met for all vaccine-matched strains.
4. Safety results indicated that most adverse reactions were of mild to moderate severity and resolved within a few days.
5. The mRNA platform offers potential advantages, including avoidance of egg adaptation–related changes and the potential for broad immunity and robust T-cell responses.
6. Health-related quality of life was evaluated, with a transient decline observed postvaccination, which resolved within a few days.
7. The study suggests that the mRNA-1083 vaccine may improve coverage and compliance with immunization guidelines, potentially reducing disease burden and strain on health care systems.

Source: JAMA